The Tumor Lysis Syndrome
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An important consideration with respect to safety in patients that may have a compromised immune system is that engineered bacterial products are likely to engage both innate and adaptive immunity in the event of release of the organism into the body following tumor lysis75, triggering inflammatory responses.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Self-citationCairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationOral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Cited by
Items 501–600 of 1,000
Zhao, J., Miller, H., & Blake, E. A. (2021) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2021.100761 · Cited by 6
Drozd-Sokolowska, J. E., Mądry, K., Siewiorek, K., Feliksbrot‐Bratosiewicz, M., Stokłosa, T., Gierej, B., Stefaniak, A., Paszkowska‐Kowalewska, M., Sokołowski, J., Sankowski, B., et al. (2022) · Chemotherapy · doi:10.1159/000524182 · Cited by 6
Cozad, M., Stump, S. E., Buhlinger, K. M., Collins, J. B., Muir, M., Coombs, C. C., & Muluneh, B. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2047963 · Cited by 6
“Howard’s criteria [13] were used to define laboratory and clinical TLS.”
MethodIto, T., Ohta, T., Narumi, M., Sakaki, H., Seino, M., Sudo, T., & Nagase, S. (2018) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2018.02.005 · Cited by 6
“Effective prevention of TLS involves monitoring fluid and electrolyte conditions, active hydration, and diuresis with administration of allopurinol or rasburicase before chemotherapy (Cario and Bishop, 2004; Cario et al., 2010; Coiffier et al., 2008; Howard et al., 2011).”
Background(2020) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2020.s59 · Cited by 6
Yen, T., Chang, C., & Shiu, S. (2020) · Case Reports in Gastroenterology · doi:10.1159/000508583 · Cited by 6
Targeted Drugs for Cancer Therapy: Small Molecules and Monoclonal Antibodies
Baldo, B. A., & Pham, N. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-51740-3_14 · Cited by 6
Armitage, K. B., Kapoor, B. S., Kalva, S. P., & Faramarzalian, A. (2015) · Seminars in Interventional Radiology · doi:10.1055/s-0035-1549379 · Cited by 6
A hypothetical method for controlling highly glycolytic cancers and metastases
Mathews, E. H., Mathews, G. E., & Meyer, A. A. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.014 · Cited by 6
Akl, M. M., & Ahmed, A. K. K. (2024) · Qeios · doi:10.32388/ebckfo.4 · Cited by 6
Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift
Tantawy, M. N., McIntyre, J. O., Yull, F. E., Calcutt, M. W., Koktysh, D. S., Wilson, A. J., Zu, Z., Nyman, J. S., Rhoades, J., Peterson, T. E., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.6812 · Cited by 5
“86 While some increased apoptosis ( ~ 10% increase) and reduced Ki 67( ~ 10% reduction) was detected in the tumors at 24 h post treatment with NSPS compared to controls (see supplementary Figure S8), apoptosis was detected throughout the tumors by 1 week post NSPS treatment (see Figure 7).”
ResultSreedharan, L., Venkiteswaran, S., Prasad, M., Anand, K. C., Bhat, K. V., Dhanaki, N., Arolkar, P., Gala, R. M., Raj, R., S, N. S., et al. (2024) · Journal of Nutrition Research · doi:10.55289/jnutres/v12i1_23.31 · Cited by 5
Koshiishi, M., Sueki, Y., Kawashima, I., Nakajima, K., Mitsumori, T., & Kirito, K. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8706-16 · Cited by 5
“TLS is an oncological emergency that is characterized by metabolic abnormalities, including hyperuricemia, hypophosphatemia, hyperkalemia and hypocalcemia (11).”
BackgroundAn Update of Venetoclax and Obinutuzumab in Chronic Lymphocytic Leukemia
Salvaris, R., & Opat, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0640 · Cited by 5
Rajšić, I., Lazarević, S., Đanić, M., Al‐Salami, H., Mooranian, A., Vukmirović, S., Mikov, M., & Goločorbin-Kon, S. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00726-9 · Cited by 5
“The rapid lysis of large numbers of highly susceptible tumor cells leads to an excessive load of released intracellular constituents [42, 43].”
BackgroundWatanabe, S., Nanke, I., Uchidate, K., Machida, T., Igarashi, A., Kobashi, K., Negi, M., & Yauchi, T. (2022) · International Cancer Conference Journal · doi:10.1007/s13691-021-00514-x · Cited by 5
“These metabolic complications can progress to clinical toxic states, including renal insufficiency, cardiac arrhythmias, seizures, and death due to multiorgan failure [1, 2].”
BackgroundAcute Kidney Injury Epidemiology and Causes
Wijayaratne, D. R., Beligaswatta, C., & Harber, M. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-76419-7_8 · Cited by 5
Whole-process management of complications during CAR-T therapy
Li, Y., & Mei, H. (2022) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0005 · Cited by 5
“Massive release of proinflammatory cytokines, tumor cell lysis and immunodeficiency can trigger many complications, including CRS, ICANS, CAR-T associated coagulopathy (CARAC), infections, CAR-T-cell-associated hemophagocytic lymphohistiocytosis/macrophage-activation syndrome (carHLH/MAS) and tumor lysis syndrome (TLS…”
BackgroundInfluentialSchwaner, I., Kuhn, T., Losem, C. J., Wolff, T. E., Otremba, B. J., Zaiss, M. R., Hülsenbeck, J., Famulla, K., Nösslinger, T., & Rossi, D. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05638-7 · Cited by 5
“TLS events were documented by the physician and recorded as laboratory and/or clinical TLS according to the definition by Howard et al. [ 18].”
BackgroundMethodSyndromes paranéoplasiques à expression rénale et atteintes rénales des cancers
Thariat, J., Vendrely, B., Roca, S., Ravaud, A., Bay, J., Lacout, A., Marcy, P. Y., Thyss, A., & Besancenot, J.-F. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2011.1491 · Cited by 5
“Le tableau s’installe alors habituellement entre un et cinq jours après le début du traitement [25].”
BackgroundDupré, A., Mousseaux, C., Bouguerba, A., Ayed, S., Barchazs, J., Boukari, M., Goldgran-Tolédano, D., Bornstain, C., & Vincent, F. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.08.021 · Cited by 5
Krebspatienten in der operativen Intensivmedizin
Annecke, T., Höhn, A., Böll, B., & Kochanek, M. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0406-9 · Cited by 5
Tumour lysis in newborn: spontaneous or secondary to antenatal steroids?
Ponmudi, N. J., Beryl, S., Santhanam, S., & Beck, M. M. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-223107 · Cited by 5
Bose, P., & Gandhi, V. V. (2021) · Faculty Reviews · doi:10.12703/r/10-22 · Cited by 5
Leukostase und Tumorlyse: Wichtige Komplikationen der Hyperleukozytose
Schellongowski, P., & Staudinger, T. (2013) · Der Internist · doi:10.1007/s00108-013-3260-5 · Cited by 5
Tseng, R.-H., Wu, C.-H., Wu, K., Lai, G.-M., & Lin, J. (2016) · Journal of Cancer Research and Practice · doi:10.1016/j.jcrpr.2016.03.001 · Cited by 5
Gouveia, H. S., Lopes, S. O., & Faria, A. L. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-223474 · Cited by 5
McKenna, S., Cheung, A., Wolfe, A., Coleman, B. L., Detsky, M. E., Munshi, L., Maze, D. C., & Burry, L. D. (2019) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v72i6.2943 · Cited by 5
“30 Acute myeloid leukemia 27 (47) 13 (45) 14 (48) Acute lymphoblastic leukemia 17 (29) 9 (31) 8 (28) Acute promyelocytic leukemia (APL) 6 (10) 5 (17) 1 (3) Diffuse large B-cell lymphoma 7 (12) 2 (7) 5 (17) Burkitt lymphoma 1 (2) 0 (0) 1 (3) Cytotoxic therapy before admission Any cytotoxic agent 26 (45) 14 (48) 12 (41)…”
InfluentialTumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma
Lingamaneni, P., Desai, P., Vennikandam, M. M., Moturi, K. R., Baranwal, A., & Gupta, S. (2020) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709620933427 · Cited by 5
Monroy, R. H., Espinosa-Sevilla, A., & Salmorán, H. O. (2020) · Acta Médica Grupo Ángeles · doi:10.35366/93892 · Cited by 5
Vachhani, P. J., Baron, J. I., Freyer, C. W., Miller, A., Wetzler, M., Thompson, J. E., Griffiths, E. A., & Wang, E. S. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106588 · Cited by 5
Spontaneous tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: a case report
Chen, K., Xie, W., Huang, Y., Jin, X., Chen, G., Wu, D., & Chen, J. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.53 · Cited by 5
“TLS commonly occurs in hematologic cancers in view of their high cell turnover, rapid proliferation rates and increased chemosensitivity (4).”
BackgroundCost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome
Patel, S., Le, A., & Gascon, S. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110656 · Cited by 5
Kunstel, K. L. (2016) · Physician Assistant Clinics · doi:10.1016/j.cpha.2016.03.002 · Cited by 5
Arikpo, K. E., Iwara, I. A., Zaruwa, M. Z., Nweze, C. C., Joseph, B. C., Samiu, A. O., Abara, U. V., Onyisi, C. O., Ogbu, S. C., & Muhammad, A. J. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100418 · Cited by 4
Eyre, T. A., Song, Y., Hermine, O., Shuang, Y.-R., Jurczak, W. J., Farias, J. S. D. H., Mahuad, C. V., Özcan, M., Jachimowicz, R. D., Chen, T., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00550 · Cited by 4
Shenoy, T., Sanchez-Almanzar, D., Dias, J., Hayden, R., Shashaty, M. G. S., Aklilu, A. M., Patell, R. D., Anand, S., Renaghan, A. D., Bassil, C., et al. (2026) · BMJ · doi:10.1136/bmj-2026-100040 · Cited by 4
Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond
Khodke, P., & Kumbhar, B. V. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.001 · Cited by 4
[Methods of shifting body weight in patients with knee arthroses].
Viton, J. M., Atlani, L., Mesure, S., Franceschi, J.-P., Massion, J., Rochwerger, A., & Delarque, A. (1998) · PubMed · Cited by 4
Expression and Clinical Significance of Spi-B in B-cell Acute Lymphoblastic Leukemia
Ariga, Y., Low, S., Hoshino, H., Nakada, T., Akama, T. O., Muramoto, A., Fukushima, M., Yamauchi, T., Ohshima, Y., & Kobayashi, M. (2022) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554221130383 · Cited by 4
Atchley, E., Weis, T. M., Derkach, A., Galera, P. K., Xiao, W., Glass, J. L., DeWolf, S., Roshal, M., Shah, R., & Stump, S. E. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107311 · Cited by 4
Pregnancy and Acute Lymphoblastic Leukemia: A Case Series and Review of Literature
Bhattacharjee, S., Ghosh, S., Ray, S. S., Samanta, S. K., Sinha, N., Saha, S., & Bhattacharyya, M. (2023) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0043-1766129 · Cited by 4
“33 Chemotherapy-induced neutropenia increases the chance of infections in the mother and poses numerous risks during pregnancy, both to the mother and the fetus.”
Important Considerations in the Intensive Care Management of Acute Leukemias
Pourhassan, H., Kareem, W., Agrawal, V., & Aldoss, I. T. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231193955 · Cited by 4
Hong, G. (2023) · Medicina · doi:10.3390/medicina59122144 · Cited by 4
“Tumor lysis syndrome (TLS) is a life-threatening oncological emergency that typically results from the lysis of rapidly proliferating malignant cells with a high tumor burden, such as hematological malignancies after the initiation of cytotoxic chemotherapy [1–4].”
BackgroundSpontaneous tumour lysis secondary to gastric adenocarcinoma
Prasad, A., Verghese, D., Rangan, S. V., & Sunadarajan, N. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-258369 · Cited by 4
A case report of fatal anaphylaxis on first exposure to rasburicase just before lymphoma treatment
Utsu, Y., Kaneda, N., Kawakami, M., Masuda, S., Arai, H., Shimoji, S., Matsumoto, R., Tsushima, T., Tanaka, K., Matsuo, K., et al. (2024) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-024-00920-9 · Cited by 4
“Currently, with the accumulation of experience on its use, rasburicase has become widely recommended and is used as a prophylactic agent for high-risk patients (and some intermediate-risk patients) with tumor lysis syndrome (TLS) with various types of malignant tumor [6–8].”
BackgroundInfluentialLo, Y., Tsai, M., Kuo, C., Liu, W., Lee, R., Yeh, Y., Li, C., Chen, J.-Y., & Chao, Y. (2012) · Acta Radiologica Open · doi:10.1258/arsr.2012.110011 · Cited by 4
Acute Respiratory Failure in the Oncologic Patient: New Era, New Issues
Ferreyro, B. L., & Munshi, L. (2019) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-030-06067-1_3 · Cited by 4
Luminais, S. N., Chen, X. T., Roman, D., Ma, B., Christ, A. B., & Hu, J. S. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03469-6 · Cited by 4
“The majority of reported TLS cases have occurred in hematologic malignancies with rapid cellular turnover such as Burkitt’s lymphoma and various leukemias [20], though TLS has occasionally been described in mesenchymalderived tumors.”
BackgroundBenitez-Escobar, E. N., Galindes-Casanova, D. A., Melo-Burbano, L. Á., Bonilla-Bonilla, D. M., Osorio-Toro, L. M., Daza-Arana, J. E., Dávila, S. L. E., & Tafurt, G. P. R. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-111 · Cited by 4
Cao, L., & Zhang, W. (2024) · Oncology Letters · doi:10.3892/ol.2024.14513 · Cited by 4
“In the present case, despite the primary lung lesion measuring only 36 mm in diameter, the patient had multiple metastatic lymph nodes across several areas (1R/L, 2R, 3A, 4R/L, 5, 6, 7 and 10R/L), contributing to a substantial overall tumor burden.”
BackgroundMohamad, J., Bouroumeau, A., McKee, T., Mach, N., Samii, K., Chamuleau, M. E. D., Stenner, F., Tamburini, J., & Lang, N. (2024) · Cancer Reports · doi:10.1002/cnr2.1983 · Cited by 4
“7,23,27 In our study population, the prevalence of TLS was higher among BL patients, constituting 57% of all TLS cases.”
BackgroundSpontaneous tumor lysis syndrome in breast cancer: a case report and discussion
Elfar, A., Teleb, M., Rodriguez-Castro, C. E., & Nahleh, Z. A. (2013) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-2-9 · Cited by 4
Acute Tubular Injury and Acute Tubular Necrosis
Turner, J. M., & Coca, S. G. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4617-0.00034-0 · Cited by 4
Variable Potassium Concentrations: Which Is Right and Which Is Wrong?
Theparee, T., Benirschke, R. C., & Lee, H.-K. (2017) · Laboratory Medicine · doi:10.1093/labmed/lmx015 · Cited by 4
Mineral and bone disorders in chronic heart failure
Reznik, E. V., & Nikitin, I. G. (2018) · Kardiologiia · doi:10.18087/cardio.2429 · Cited by 4
“Гиперфосфатемия при СН может объясняться, во-первых, тканевой гипоксией, имеющей место при выраженных стадиях СН и способной индуцировать выход фосфора из клеток подобный тому, который наблюдается при синдроме лизиса опухоли [50].”
Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma
Pabon, C. M., Esnakula, A. K., & Daily, K. C. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224576 · Cited by 4
Oshima, M., Mayumi, S., Yazaki, K., Nakamura, Y., Konishi, T., Saito, K., Washino, S., & Miyagawa, T. (2019) · IJU Case Reports · doi:10.1002/iju5.12070 · Cited by 4
Tumor Lysis Syndrome: A Practical Guide for Nurse Practitioners
Ly, T.-T. T., & Winokur, E. J. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.06.005 · Cited by 4
Park, S. H., Lim, J., Jeong, J., Lee, S., Cha, H. J., Choi, Y., & Jo, J. (2019) · Blood Research · doi:10.5045/br.2019.54.3.231 · Cited by 4
“A previous study demonstrated that TLS associated with therapy involves higher levels of phosphorus due to cell destruction and STLS involves lower levels of phosphorus due to its reutilization in the synthesis of new tumor cells [8].”
BackgroundPATEL, V. G., & Case, R. (2020) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709620944709 · Cited by 4
Spontaneous tumour lysis syndrome in multiple myeloma with loss of 17p13.1, t(4;14) and monosomy 13
Tbakhi, B., Hanna, S., Samhouri, Y., & Lingutla, D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2019-234122 · Cited by 4
Tumor Lysis Syndrome in a Low-Risk Pancreatic Cancer Patient
Travers, P. M., Goodman, A., & Poiesz, B. J. (2021) · Case Reports in Oncology · doi:10.1159/000512827 · Cited by 4
Howard, S. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00036-0 · Cited by 4
Self-citationWacker, D. A., & McCurdy, M. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-28794-8_29 · Cited by 4
Juliansen, A., Andriastuti, M., Pardede, S. O., & Sekartini, R. (2014) · Paediatrica Indonesiana · doi:10.14238/pi54.6.2014.372-6 · Cited by 4
Navigating Through the Complications of Chronic Immunosuppression in Transplant Patients
Amaeshi, L. C. (2022) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2022.0940 · Cited by 4
Tumor Lysis Syndrome Rare Presentation As Uremic Pericarditis: A Case Report
Emídio, F. C., Pereira, R., dos Santos, P. M., & Abegão, T. (2023) · Cureus · doi:10.7759/cureus.35727 · Cited by 3
“Due to the reserved prognosis with which it is associated, the prevention of its occurrence per se, as well as its consequences, is mandatory [1,6].”
BackgroundNephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma
Chen, Z., Chen, Y., Liu, J., Sun, Y., Zhang, X., Shao, L., Wang, D., Wang, X., Chen, W., Sang, W., et al. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04503-4 · Cited by 3
“Uric acid can cause AKI by inducing renal vasoconstriction, oxidative reactions, and inflammation that are not dependent on crystal deposition [31].”
High risk and low incidence diseases: Tumor lysis syndrome
Molyneux, K., Beck‐Esmay, J., Koyfman, A., & Long, B. (2025) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2025.08.067 · Cited by 3
Wang, W., Dong, Z., Miao, Q., Hong, B., Bo, Y., Zhang, X., Guan, X., & Zhang, N. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.08.001 · Cited by 3
Short piece: metabolic acidosis
Jung, B., Forni, L. G., & Jaber, S. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08200-9 · Cited by 3
“In patients presenting with tumor lysis syndrome, there is a risk of calcium phosphate precipitation and further kidney injury [14].”
Toxins and the Kidneys: A Two-Way Street
Huang, L., Longano, A., & McMahon, L. P. (2025) · Toxins · doi:10.3390/toxins17120578 · Cited by 3
“What followed was a combination of renal tubular occlusion from uric acid crystals, as well as a pro-inflammatory and pro-apoptotic response—involving upregulation of cytokines such as intracellular adhesion molecule-1 and caspase-1—that resulted in further tubular cell injury and apoptosis [61].”
Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit
Rodriguez, C., Touzeau, C., Crusoé, E. D. Q., Pericole, F. V., & Hungria, V. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.015 · Cited by 3
Soboleva, A., Honasoge, K. S., Molnárová, E., Mulders, T. A., Dingemans, A. C., Grossmann, I., Rezaei, J., & Staňková, K. (2026) · Journal of Evolutionary Biology · doi:10.1093/jeb/voag107 · Cited by 3
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience
Takai, M., Yamauchi, T., Matsuda, Y., Tai, K., Ikegaya, S., Kishi, S., Urasaki, Y., Yoshida, A., Iwasaki, H., & Ueda, T. (2015) · Oncology Letters · doi:10.3892/ol.2015.3009 · Cited by 3
“This process can potentially cause hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia, thereby inducing renal insufficiency, cardiac arrhythmias, seizures and neurological disorders, ultimately resulting in mortality (1-6).”
Nguyen, K.-P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108668736.045 · Cited by 3
A case report of tumor lysis syndrome after stage-one ALPPS
Cheung, B. H. H., She, W. H., Yap, D. Y. H., Tsang, S. H. Y., & Cheung, T. T. (2022) · Medicine · doi:10.1097/md.0000000000029040 · Cited by 3
“Compared with allopurinol, febuxostat has a higher potency due to its action to oxidized and reduced forms of xanthine oxidase.([2]) It also requires no renal adjustment and has a lower risk of hypersensitivity.”
BackgroundInfluentialMasui, H., Shindo, M., Inoue, Y., Sugiyama, M., Ueda, A., Shindo, T., Okoshi, K., & Kinoshita, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14355 · Cited by 3
“If only chemotherapy had been administered without surgical intervention, there would have been a potential risk of triggering a severe tumor lysis syndrome and exacerbating pre‑existing HLH due to the high tumor burden (28).”
BackgroundJhetam, Z., Martins-Furness, C., Slabber, C., Munro, O. Q., Nel, M., & Harmse, L. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112815 · Cited by 3
de Boer, A., McCaw, C., Ackman, M. L., Leslie, T., Peters, A., & Koshman, S. L. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251324522 · Cited by 3
Serre, J., Mulier, G., Boud’hors, C., Lemerle, M., Abdel-Nabey, M., Orvain, C., Chaba, A., Biard, L., Demiselle, J., & Zafrani, L. (2025) · Annals of Intensive Care · doi:10.1186/s13613-025-01439-x · Cited by 3
“This process induces calcium phosphate nephropathy, subsequently causing AKI, which further exacerbates hyperphosphatemia, thus creating a vicious cycle [5, 27].”
Wali, A. F., Talath, S., Sridhar, S. B., El‐Tanani, M., & Rangraze, I. R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167852 · Cited by 3
Wang, J., Xie, T., Peng, J., Zhang, Y., & Zhang, H. (2025) · Health Data Science · doi:10.34133/hds.0325 · Cited by 3
“TLS involves the rapid release of large amounts of intracellular substances (such as potassium, uric acid, calcium, and phosphorus) [ 54 , 55 ], resulting in the precipitation of phosphate and uric acid and the blockage of the renal tubules, leading to AKI.”
Management of acute kidney injury in tumor lysis syndrome: a narrative review
Zeppilli, L., Morabito, S., Gigante, A., & Pistolesi, V. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04050-x · Cited by 3
“TLS most commonly occurs in the setting of bulky hematologic malignancies such as non-Hodgkin’s lymphoma (NHL) or acute myeloid leukemia (AML), but it has also been reported in solid tumors such as small cell carcinoma or breast cancer [1, 18–20].”
InfluentialA unifying diagnosis for pancytopenia, fever, hypoglycemia, and lactic acidosis
Kloesel, B., Vaidya, R., Howard, M. T., & Thompson, C. A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23178 · Cited by 3
“I would treat with rasburicase and aggressive intravenous fluid therapy prior to chemotherapy initiation to reduce the risk of end-organ damage [13].”
BackgroundBrooks, J., Huancahuari, N., & Wittels, K. A. (2014) · MedEdPORTAL · doi:10.15766/mep_2374-8265.9770 · Cited by 3
Arrhythmias and Electrolyte Imbalances as Consequences of Cancer
Maurea, N., Parrini, I., & Lestuzzi, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-40236-9_5 · Cited by 3
Sørensen, N. N., Jensen, P., Clasen‐Linde, E., Larsen, J. M., & El‐Galaly, T. C. (2018) · Clinical Case Reports · doi:10.1002/ccr3.1390 · Cited by 3
“The release of intracellular tumor cell content (potassium, phosphorus, and uric acid) into the bloodstream leads to critical hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia [1].”
BackgroundRituxan-Induced Tumor Lysis Syndrome in a Patient With Diffuse Large B-Cell Lymphoma
Iftikhar, S., Khokher, W., Gekonde, J., Kesireddy, N., & Mudiyanselage, P. H. (2021) · Cureus · doi:10.7759/cureus.16921 · Cited by 3
“The accumulation of these can result in end-organ damage effects namely, acute renal failure, cardiac arrhythmias, seizures, and eventual demise secondary to multi-organ failure [2].”
BackgroundManaging Issues: Tumor Lysis, Extravasation, Adverse Effects, and Others
Frigo, L., da Fonseca, G. A. M. D., Fávero, G. M., & Maria, D. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98596-7_11 · Cited by 3
Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma
Kim, S. Y., Kim, H. Y., Kim, Y., Lee, S. M., & Kim, C. W. (2015) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2015.32.1.47 · Cited by 3
“This syndrome is caused by release of the contents of malignant cells to blood, either spontaneously or in response to effective therapy [2].”
BackgroundInfluentialAcute renal failure in patients with tumour lysis sindrome
Poskurica, M., Petrović, D., & Poskurica, M. (2016) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1604232p · Cited by 3
Spurious Results in Mineral and Electrolyte Analysis
Gorman, E. (2017) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2016.10.019 · Cited by 3
“Occasionally, these patients also show pseudohyperphosphatemia (depending on the technique used to measure it) and thus the condition may be mistaken for tumor lysis syndrome, which is rare but often fatal.(13,29)”
Metabolische Entgleisungen als paraneoplastische Syndrome
Krug, S., & Michl, P. (2017) · Der Internist · doi:10.1007/s00108-017-0357-2 · Cited by 3
Krebspatienten in der operativen Intensivmedizin
Annecke, T., Höhn, A., Böll, B., & Kochanek, M. (2018) · Wiener klinisches Magazin · doi:10.1007/s00740-018-0218-1 · Cited by 3
Clinical Manifestations and Treatment of Childhood Acute Lymphoblastic Leukemia
Jeha, S., & Pui, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00065-2 · Cited by 3
Self-citationTumor Lysis Syndrome After Bilobectomy for Typical Carcinoid Tumor of the Lung
Shin, T. H., Inagaki, E., Ganta, T., Hartshorn, K. L., Litle, V. R., & Suzuki, K. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.06.089 · Cited by 3
Postoperative Nausea and Vomiting in Children
Chandrakantan, A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108668736.006 · Cited by 3
In Silico Structural and Functional Analysis of Bacillus Uricases
Nelapati, A. K., Meena, S., Singh, A. K., Bhakta, N., & JagadeeshBabu, P. E. (2020) · Current Proteomics · doi:10.2174/1570164617999200512081127 · Cited by 3
Metadata
- Authors
- Howard, S. C., Jones, D. P., & Pui, C.-H.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-12
- Volume
- 364
- Issue
- 19
- Pages
- 1844-1854
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3437249
- OpenAlex
- W2122479144
- Cited by
- 1,044
- References
- 58
- Citations by year
- 2026: 71 · 2025: 67 · 2024: 86 · 2023: 71 · 2022: 69 · 2021: 81 · 2020: 89 · 2019: 154 · 2018: 60 · 2017: 53 · 2016: 49 · 2015: 57 · 2014: 47 · 2013: 49 · 2012: 31
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA21765, P30CA021765)
- National Institute of General Medical Sciences (U01GM92666, U01GM092666)
- Topics
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Keywords
- tumor lysis syndrome, hematologic malignancies, risk assessment, prophylaxis, treatment, pediatric oncology, emergency management
- MeSH terms
- Child, Humans, Male, Tumor Lysis Syndrome, Risk Assessment, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.